Thus, through the promotion of anti-cancer immunity through multiple parallel pathways, activation of NRF2 by Sotorasib and Adagrasib positively contributes to the clinical efficacy of this novel class of anti-cancer drugs. The gene discussed is NFE2L2; the disease is cancer.